Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Tap

Showing results (161-170 of 235) with videos related to

Pageof 24
Sort By:
JCO Precision Oncology|August 11, 2022
Prospective Clinical Genomic Profiling of Ewing Sarcoma: <i>ERF</i> and <i>FGFR1</i> Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic RelevanceKoichi Ogura, Arielle Elkrief, Anita S Bowman, et al.
Cancer Research Communications|October 3, 2023
Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced SarcomasEvan Rosenbaum, Kenneth Seier, Martina Bradic, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 2, 2023
Stereotactic body radiation therapy for sarcoma pulmonary metastasesEmily S Lebow, Stephanie M Lobaugh, Zhigang Zhang, et al.
Cancer|November 16, 2020
Long-term outcomes of pexidartinib in tenosynovial giant cell tumorsHans Gelderblom, Andrew J Wagner, William D Tap, et al.
JCO Precision Oncology|December 7, 2020
Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway GenesEvan Rosenbaum, Philip Jonsson, Kenneth Seier, et al.
Investigational New Drugs|August 14, 2018
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumorCiara M Kelly, Alexander N Shoushtari, Li-Xuan Qin, et al.
Future Oncology (London, England)|January 18, 2022
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burdenCharles Peterfy, Yan Chen, Peter Countryman, et al.
The Oncologist|January 16, 2021
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of TherapySuzanne George, Robin L Jones, Sebastian Bauer, et al.
The Lancet. Oncology|July 8, 2024
Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort studyDimitris Bertsimas, Georgios Antonios Margonis, Suleeporn Sujichantararat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialSuzanne George, Qian Wang, Michael C Heinrich, et al.
Pageof 24

Showing results (161-170 of 235) with videos related to

Sort By:
Pageof 24
JCO Precision Oncology|August 11, 2022
Prospective Clinical Genomic Profiling of Ewing Sarcoma: <i>ERF</i> and <i>FGFR1</i> Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic RelevanceKoichi Ogura, Arielle Elkrief, Anita S Bowman, et al.
Cancer Research Communications|October 3, 2023
Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced SarcomasEvan Rosenbaum, Kenneth Seier, Martina Bradic, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 2, 2023
Stereotactic body radiation therapy for sarcoma pulmonary metastasesEmily S Lebow, Stephanie M Lobaugh, Zhigang Zhang, et al.
Cancer|November 16, 2020
Long-term outcomes of pexidartinib in tenosynovial giant cell tumorsHans Gelderblom, Andrew J Wagner, William D Tap, et al.
JCO Precision Oncology|December 7, 2020
Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway GenesEvan Rosenbaum, Philip Jonsson, Kenneth Seier, et al.
Investigational New Drugs|August 14, 2018
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumorCiara M Kelly, Alexander N Shoushtari, Li-Xuan Qin, et al.
Future Oncology (London, England)|January 18, 2022
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burdenCharles Peterfy, Yan Chen, Peter Countryman, et al.
The Oncologist|January 16, 2021
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of TherapySuzanne George, Robin L Jones, Sebastian Bauer, et al.
The Lancet. Oncology|July 8, 2024
Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort studyDimitris Bertsimas, Georgios Antonios Margonis, Suleeporn Sujichantararat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialSuzanne George, Qian Wang, Michael C Heinrich, et al.
Pageof 24